Semaglutide Resolves MASH in 62.9% of Patients Without Worsening Fibrosis, Study Finds

A recent study found that a significant portion of patients with metabolic dysfunction-associated steatohepatitis (MASH) who received semaglutide experienced a resolution of the condition without their fibrosis worsening. Specifically, researchers observed this outcome in 62.9% of the MASH patients treated with semaglutide. This finding indicates that over 60% of patients with MASH saw their steatohepatitis resolve, while their liver fibrosis, a key indicator of disease progression, did not worsen during the study period. The data highlights a potential therapeutic effect of semaglutide on MASH.

Newsflash | Powered by GeneOnline AI
Date: May 6, 2025

Related posts:

Groundbreaking Study Reveals How Aging Heart Influences Brain Function Imaging Discovery Promises Faster Drug Development Immune Cells Exhibit Dual Functional Roles in Defense and Attack Study Examines Cancer Risks Associated with Red and White Wine Consumption

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後